Open AccessPoor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
Author(s) -
Zhou Jianya,
Zheng Jing,
Zhao Jing,
Sheng Yihong,
Ding Wei,
Zhou Jianying
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12146
Subject(s) - anaplastic lymphoma kinase , gefitinib , medicine , epidermal growth factor receptor , concomitant , cancer research , lung cancer , tyrosine kinase inhibitor , adenocarcinoma , tyrosine kinase , pathology , fluorescence in situ hybridization , anaplastic large cell lymphoma , cancer , lymphoma , biology , malignant pleural effusion , receptor , biochemistry , gene , chromosome
A patient presenting with concomitant epidermal growth factor receptor ( EGFR) mutation and anaplastic lymphoma kinase ( ALK) translocation is rare. We report a non‐small cell lung cancer ( NSCLC) patient with concomitant ALK rearrangement and exon 19 ( E746‐A750del ) EGFR mutation. The ALK rearrangement was confirmed not only in the primary tumor biopsy specimen, but also in the pleural effusion cell block by reverse transcriptase‐polymerase chain reaction ( RT‐PCR) , V entana ALK immunohistochemistry assay, and fluorescence in situ hybridization. No clinical benefit using chemotherapy or EGFR tyrosine kinase inhibitor gefitinib was obtained in this case.